Literature DB >> 12526040

Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses.

Vladimir P Chulanov1, German A Shipulin, Stephan Schaefer, Wolfram H Gerlich.   

Abstract

The kinetics of hepatitis B virus (HBV) and its surface antigen (HBsAg) during acute hepatitis has not yet been studied accurately in a representative number of patients. The influence of coinfecting hepatitis viruses during the acute phase of infection is not known. Three to four serum samples from 21 patients with acute HBV monoinfection and 27 with coinfection were taken at intervals of 6-10 days and analyzed for the number of HBV genome equivalents (ge) by real time polymerase chain reaction (PCR) and for HBsAg quantity using Laurell electrophoresis. Log HBV ge/ml decreased during the follow-up from 6.8 +/- 1.1 to 5.1 +/- 1.0 to 4.2 +/- 0.8 to 3.3 +/- 1.1 (mean +/- SD). The half-life times of HBV ge increased from 1.6 days at the beginning to 4 days at the end. HBsAg decreased much slower: from 38 to 23 to 12 to 3.8 microg/ml. Half-life time was around 8 days at the beginning and 5.7 days at the end, but 11 patients showed a rapid elimination of HBsAg and HBV DNA. Hepatitis C virus (HCV) coinfection did not change the kinetics of HBV ge and HBsAg significantly. A moderate but significant suppression of HBV ge levels was observed in hepatitis D virus (HDV) coinfected patients. HBsAg levels were, however, enhanced in this cohort. In conclusion, the data suggest that expression and elimination of HBV is in most patients with acute hepatitis B not altered by coinfecting hepatitis viruses. The initial decrease of HBV ge and HBsAg in serum appears to be caused by decay or non-specific removal in the absence of replacement. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12526040     DOI: 10.1002/jmv.10291

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

2.  Management of hepatitis B virus-related acute liver failure.

Authors:  Makoto Oketani; Hirofumi Uto; Akio Ido; Hirohito Tsubouchi
Journal:  Clin J Gastroenterol       Date:  2014-01-24

3.  Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses.

Authors:  Teresa Pollicino; Giuseppina Raffa; Teresa Santantonio; Giovanni Battista Gaeta; Giuliano Iannello; Angela Alibrandi; Giovanni Squadrito; Irene Cacciola; Chiara Calvi; Giuseppe Colucci; Massimo Levrero; Giovanni Raimondo
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

4.  Clinical, epidemiological and virological features of acute hepatitis B in Italy.

Authors:  Ornella Zuccaro; Luisa Romanò; Alfonso Mele; Andrea Mariano; Massimo Clementi; Maria Elena Tosti; Gloria Taliani; Claudio Galli; Alessandro Remo Zanetti; Enea Spada
Journal:  Infection       Date:  2015-02-20       Impact factor: 3.553

5.  Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Authors:  Dieter Glebe; Heike Lorenz; Wolfram H Gerlich; Scott D Butler; Ilia A Tochkov; Bud C Tennant; Paul Cote; Stephan Menne
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

Review 6.  Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).

Authors:  R Bruno; G Carosi; N Coppola; G B Gaeta; M Puoti; T Santantonio; G Taliani; O Armignacco; E Sagnelli; M Andreoni; G Angarano; G Di Perri; G D'Offizi; M Galli; G Rizzardini
Journal:  Infection       Date:  2014-07-06       Impact factor: 3.553

7.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 8.  Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-18       Impact factor: 3.267

9.  Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.

Authors:  Tung-Hung Su; Chun-Jen Liu; Tai-Chung Tseng; Chen-Hua Liu; Hung-Chih Yang; Chi-Ling Chen; Pei-Jer Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China.

Authors:  H W Zhang; J H Yin; Y T Li; C Z Li; H Ren; C Y Gu; H Y Wu; X S Liang; P Zhang; J F Zhao; X J Tan; W Lu; S Schaefer; G W Cao
Journal:  Gut       Date:  2008-08-28       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.